B cells in MS: Why, where and how?

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), in which auto-aggressive lymphocytes participate in inflammation that causes myelin destruction. Although T lymphocytes have been viewed as important culprits in the inflammatory cascade that results in MS, clinical trial results and animal model data support a role for B lymphocytes in MS pathology. In spite of these encouraging results, the mechanism behind why B cell depletion might be effective for MS treatment remains unknown. Herein we summarize the state of our knowledge for how B cells and their antibody products may influence the initiation and or propagation of MS, drawing from human studies and animal model data.

► B cell depletion (Rituximab) in RRMS patients results in improved clinical outcomes.
► The mechanism of action of Rituximab therapy remains unclear.
► “Follicle-like structures” within the CNS meninges may support B cells during MS.
► Ab-dependent and Ab-independent functions of B cells may contribute to MS.